Bluebird Bio Stock Performance
BLUE Stock | USD 0.92 0.05 5.15% |
The firm shows a Beta (market volatility) of 4.09, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bluebird Bio will likely underperform. Bluebird bio right now shows a risk of 6.95%. Please confirm Bluebird bio skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Bluebird bio will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bluebird bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Bluebird Bio is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Last Split Factor 1544:1000 | Last Split Date 2021-11-05 |
1 | Exercise or conversion by Jeffrey Walsh of 100 shares of Bluebird Bio subject to Rule 16b-3 | 02/02/2024 |
2 | Sale by Jeffrey Walsh of 300 shares of Bluebird Bio | 02/21/2024 |
3 | Shareholders that lost money on bluebird bio, Inc. should contact Levi Korsinsky about pending Class Action - BLUE | 04/09/2024 |
4 | bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 04/11/2024 |
5 | Bit by a billionaires dog Or a case of extortion A legal saga from an L.A. dog park | 04/16/2024 |
6 | Investors who lost money on bluebird bio, Inc. should contact The Gross Law Firm about pending Class Action - BLUE | 04/17/2024 |
7 | Shareholders that lost money on bluebird bio, Inc. Urged to Join Class Action - Contact Levi Korsinsky to Learn More | 04/18/2024 |
8 | Investors who lost money on bluebird bio, Inc. should contact Levi Korsinsky about pending Class Action - BLUE | 04/19/2024 |
9 | Lost Money on bluebird bio, Inc. Join Class Action Suit Seeking Recovery - Contact Levi Korsinsky | 04/22/2024 |
10 | Class Action Filed Against bluebird bio, Inc. Seeking Recovery for Investors Contact Levi Korsinsky | 04/23/2024 |
Begin Period Cash Flow | 111.6 M |
Bluebird |
Bluebird Bio Relative Risk vs. Return Landscape
If you would invest 106.00 in Bluebird bio on January 26, 2024 and sell it today you would lose (14.00) from holding Bluebird bio or give up 13.21% of portfolio value over 90 days. Bluebird bio is currently generating 0.0053% in daily expected returns and assumes 6.9544% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of stocks are less volatile than Bluebird, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Bluebird Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bluebird Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bluebird bio, and traders can use it to determine the average amount a Bluebird Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 8.0E-4
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | BLUE |
Estimated Market Risk
6.95 actual daily | 61 61% of assets are less volatile |
Expected Return
0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bluebird Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bluebird Bio by adding Bluebird Bio to a well-diversified portfolio.
Bluebird Bio Fundamentals Growth
Bluebird Stock prices reflect investors' perceptions of the future prospects and financial health of Bluebird Bio, and Bluebird Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bluebird Stock performance.
Return On Equity | -0.48 | ||||
Return On Asset | -0.15 | ||||
Operating Margin | (6.84) % | ||||
Current Valuation | 235.54 M | ||||
Shares Outstanding | 192.74 M | ||||
Price To Earning | (19.32) X | ||||
Price To Book | 0.96 X | ||||
Price To Sales | 9.76 X | ||||
Revenue | 21.73 M | ||||
Gross Profit | (247.24 M) | ||||
EBITDA | (131.77 M) | ||||
Net Income | (91.17 M) | ||||
Cash And Equivalents | 132.51 M | ||||
Cash Per Share | 1.72 X | ||||
Total Debt | 281.39 M | ||||
Debt To Equity | 1.63 % | ||||
Current Ratio | 1.12 X | ||||
Book Value Per Share | 2.08 X | ||||
Cash Flow From Operations | (277.48 M) | ||||
Earnings Per Share | (0.63) X | ||||
Market Capitalization | 187.08 M | ||||
Total Asset | 554.9 M | ||||
Retained Earnings | (3.99 B) | ||||
Working Capital | 71.25 M | ||||
Current Asset | 523.97 M | ||||
Current Liabilities | 40.37 M | ||||
About Bluebird Bio Performance
To evaluate Bluebird bio Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Bluebird Bio generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Bluebird Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Bluebird bio market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Bluebird's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | (46.09) | (48.40) | |
Return On Tangible Assets | (0.56) | (0.59) | |
Return On Capital Employed | (0.77) | (0.81) | |
Return On Assets | (0.55) | (0.58) | |
Return On Equity | (1.56) | (1.48) |
Things to note about Bluebird bio performance evaluation
Checking the ongoing alerts about Bluebird Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bluebird bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Bluebird bio had very high historical volatility over the last 90 days | |
Bluebird bio has some characteristics of a very speculative penny stock | |
Bluebird bio has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 21.73 M. Net Loss for the year was (91.17 M) with loss before overhead, payroll, taxes, and interest of (247.24 M). | |
Bluebird bio currently holds about 132.51 M in cash with (277.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Bluebird bio has a frail financial position based on the latest SEC disclosures | |
Roughly 65.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from accesswire.com: Class Action Filed Against bluebird bio, Inc. Seeking Recovery for Investors Contact Levi Korsinsky |
- Analyzing Bluebird Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bluebird Bio's stock is overvalued or undervalued compared to its peers.
- Examining Bluebird Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bluebird Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bluebird Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bluebird Bio's stock. These opinions can provide insight into Bluebird Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Bluebird Stock analysis
When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Bluebird Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Revenue Per Share 0.214 | Quarterly Revenue Growth 173.535 | Return On Assets (0.15) | Return On Equity (0.48) |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.